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Abstract
Objective: To evaluate midazolam as an epidural analgesic in patients undergoing single-level microdiscectomy.
Methods: This prospective case control study was carried out at the Aga Khan University Hospital, Karachi, from
January 20 to September 20, 2007, on patients undergoing microdiscectomy. Cases (group A) received
midazolam with saline, while controls (group B) received saline only, placed intra-operatively over involved nerve
root. Post-operatively, patients were monitored for various variables. Data was analysed using SPSS 13.0 and
groups were compared using student's t-test for continuous variables and chi square for categorical variables.
P-value <0.05 was considered significant.
Results: Patients in group A ambulated earlier (p = 0.005) and although they did not show significantly better
post-operative pain control, but post-operative nausea and vomiting (PONV) score was better at six hours (p =
0.020). There was no difference in other variables such as requirement of analgesics, anti-emetics, hospital stay
and complications. 
Conclusion: Midazolam may improve post-operative nausea and vomiting score, and may lead to earlier
ambulation, without affecting patient's vitals, consciousness, lower extremity power or sensations, and is not
associated with adverse effects. 
Keywords: Microdiscectomy, Midazolam, Epidural analgesia, Post-operative pain (JPMA 62: 561; 2012).
Original Article
Introduction
Microdiscectomy (MD) is the surgical removal of
prolapsed intervertebral disc, and is one of the most commonly
performed neurosurgical procedures in the world with excellent
results and minimum morbidity.1 Post-operative pain remains
the major reason for increased hospital stay, days off work, and
delay in ambulation in these patients and various methods have
been proposed to minimise post-operative pain.2,3 Epidural
analgesia is widely used for post-operative pain in a variety of
surgical procedures and is recognised to provide superior
quality of analgesia when compared with systemic opioids.4
Midazolam, a water soluble benzodiazepine, produces an
analgesic action through the benzodiazepine/gamma
aminobutyric acid (GABA) receptor complex in the spinal cord.
Reported first around 1978, it is extensively used as a systemic
adjuvant in operating rooms and critical care medicine for its
sedative, anxiolytic and amnesic effects.5 Its systemic actions
and benzodiazepine pharmacology have been comprehensively
studied and are now very well understood.5Recently, its use has
been extended to epidural and intrathecal routes with
considerable success without any reported adverse effects.6-8
Since midazolam also enjoys widespread availability, low cost
and excellent patient tolerance, we hypothesise that it would be
an ideal analgesic when used as an intra-operative nerve root
and thecal sac irrigant in patients undergoing microdiscectomy
for prolapsed lumbosacral intervertebral disc. Positive results
would help to establish midazolam as an analgesic in all spine
surgeries that involve exposure of epidural space. This study
was undertaken to evaluate medazolam in patietns undergoing
microdiscectomy.
Patients and Methods
This is a prospective case control study conducted
from January 20 to September 20, 2007, at Aga Khan
University Hospital, Karachi, following approval by the
hospital's ethics review committee. All adult patients
admitted for single level (L4-5 or L5-S1) microdiscectomy
were included. Patients who were excluded were those who
either had symptoms for more than six months, spinal canal
stenosis, previous history of spine surgery, were known to
have contraindications to midazolam or who were unable to
complete the Visual Analogue Scale (VAS). Surgical
procedures with intra-operative dural tear or nerve root
damage were also excluded. Patients were enrolled during the
study period in one of the two groups; A (case group), and B
(control group), by non-probability, convenience sampling.
Thirty patients were included in each group. Patients in group
A (case group) received a 2 centimetre x 2 centimetre
absorbable gelatin sponge (Gelfoam, Upjohn Co.,
Kalamazoo, MI) soaked in 1 milligram per 1 milliliter
midazolam diluted in 1 milliliter 0.9 % isotonic saline.
Patients in group B (control group) received a similar
gelfoam soaked in 0.9 % isotonic saline alone which was
placed over the exposed nerve root and adjacent thecal sac
after having had a standard microdiscectomy. These gelfoam
pieces are absorbable and, therefore, were not removed, and
the placement was followed by wound closure. All surgeries
were performed in general anaesthesia. All efforts were made
to standardise the procedure and post-operatively patients
were managed within a standardised protocol of medications.
Additional analgesic and anti-emetic requirements were met
with intravenous Ketorolac 30 mg and intravenous
Metoclopromide 10 mg respectively. All patients were
serially monitored for pain and side effects at 1 hour, 6 hours,
12 hours, 24 hours and 48 hours post-operatively, using VAS
for pain and a pre-designed pro-forma for potential side
effects. Post-operative nausea, vomiting (PONV), sedation
and degree of ambulation, lower extremity sensations, power
and post-operative complications were also recorded using
standardised scoring systems. 
The data thus collected were entered and analysed
using SPSS version 13.0 (Chicago, IL, USA). Results are
expressed as mean ± standard deviation for continuous
variables and frequency/percentage for categorical data.
Cases and controls were compared using independent sample
student's t-test for continuous variables and chi square for
categorical variables. Tables (2x2) were used to calculate
Odd's ratios and p = <0.05 was considered significant.
Results
There were no dropouts from the study and both
groups were comparable in terms of gender distribution,
mean age (p = 0.89), duration of symptoms (p = 0.152),
operative time (p = 0.469) and hospital stay (p = 0.623).
Mean VAS of the two group of patients at different
observation times was noted (Table-1). The difference in
post-operative pain at one hour (p =0.451), six hours (p =
0.6), 12 hours (p = 0.44), 24 hours (p = 0.96) and 48 hours (p
= 0.15) were not statistically significant. By the end of first
hour post-surgery, 21 (70%) patients in group A and 10
(33.3%) patients in group B were able to ambulate without
assistance (Table-2). This difference was statistically
significant (p = 0.005, OR 0.2143, CI 95%). All of our
patients were mobilised without support by the 12th post-
operative hour. None of the patients in the study showed any
reduction in their hip joint power or lower extremity
temperature sensations or pre-operative Straight Leg Raising
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Table-1: Comparison of post-operative pain (VAS).
Group A (Cases) Group B (Controls)
Mean S D Range Mean S D Range P-value
1 hour 5.57 2.16 2-10 6.07 1.98 2-10 0.45
6 hours 4.23 1.54 2-7 4.47 1.43 2-7 0.6
12 hours 3.17 1.05 1-5 3.20 0.96 1-5 0.44
24 hours 2.60 0.77 1-4 2.57 0.77 1-4 0.96
48 hours 2.13 0.93 1-4 2.03 0.76 1-3 0.15
VAS: Visual Anologue Scale.
(SLR) at any point in their post-operative course. Sedation
scores (p = 0.072) and PONV score (p = 0.642) at one hour
were also not significant. Both these differences however,
become important at six hours (Table-3). Differences in mean
heart rates at one hour (p = 0.282), six hours (p = 0.933), 12
hours (p = 0.470), 24 hours (p = 0.924) and later, were
statistically insignificant. Differences in the requirement of
rescue analgesia at one hour (p = 0.206), six hours (p = 0.119)
and later were similarly insignificant. A total of six (10%)
patients went into post-operative urinary retention, three in
each group, all responding to non-invasive manoeuvres and
none requiring catheterisation.
Discussion
Microdiscectomy can be performed as a daycare
procedure and is being done so at a number of centres around
the world. Post-operative pain remains the major reason for
increased hospital stay, days off work, and delay in
ambulation in these patients. Patients usually report
resolution of pre-operative leg pain, but report new onset,
post-operative back pain focused mainly at the incision site.
This pain is thought to be due to the skin and fascial incision,
muscle retraction and laminotomy; and various methods have
been proposed to minimise it.2-4 Delivery of medications
directly into the epidural space provides better pain control
and improves perioperative pathophysiology, resulting in
decreased post-operative morbidity.9,10 Meta-analysis has
shown that epidural analgesia is superior to parenteral opioids
for each post-operative day, for all types of surgeries and all
types of pain assessment methods.11 The complication rates
are lower and the most commonly reported complications
include urinary retention, hypotension, lower extremity
motor blockade, paresthesias, epidural bleeding, infection,
nausea, vomiting and headaches. Epidural analgesia is liable
to failure mostly due to technical complications involved in
the administration of drug through lumbar puncture needle or
fine epidural catheter. Exposure of epidural space during
microdiscectomy provides an excellent opportunity to
administer these medications without the risk of
complications that include bleeding, cerebrospinal fluid
(CSF) leak with accompanying post-dural puncture
headaches or inadvertent intra-thecal administration. 
Midazolam is extensively used as a systemic adjuvant
in operating rooms and also in critical care medicine. Its
systemic actions and pharmacology have been
comprehensively studied and are very well understood. Its
clinical use has been extended to epidural and intra-thecal
routes with success and without adverse effects.5 It has been
shown that within the spinal cord, both the inhibitory
neurotransmitter gamma aminobutyric acid (GABA) and the
excitatory neurotransmitter glutamate are involved in
nociceptive mechanisms and may operate in concert.12,13 The
GABAA receptors are proposed to exist at the primary
afferent terminal in the spinal cord; and the GABAergic
system has been proposed to play an important role in the
presynaptic inhibition of primary afferents. Interestingly,
GABAA receptor (Cl- channel) in the spinal cord also
possess benzodiazepine binding sites.14 These
benzodiazepine receptors are concerned with pain
transmission in the dorsal horn of the spinal cord by
increasing the Cl- conductance of GABAA on the primary
afferents, hyperpolarising it and, therefore, reducing the
release of glutamate in the spinal cord.14,15 Benzodiazepine
receptor agonists increase the intrinsic efficacy of GABA at
the GABAA receptor coupling with benzodiazepine receptor
in the spinal cord. Thus, both benzodiazepines and
benzodiazepine receptor agonists may exhibit spinally
mediated anti-nociceptive effects.14,16,17 These observations
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Table-2: Comparison of post-operative unassisted ambulation (n = no. of patients).
Group A (Cases) Group B (Controls) P-value Odds Ratio Pearson Chi -square Confidence Interval (%)
1 hour 21 (70%) 10 (33.3%) 0.005 0.214 8.08 95
6 hours 26 (86.6%) 28 (93.3%) 0.335 2.153 - 95
>6 hours 30 (100%) 30 (100%) - - - -
Table-3: Comparison of PONV score.
Group A Group B P-value Odds Ratio Pearson Confidence
(Case group) (Control group) Chi -square Interval (%)
At 1 post-operative hour PONV 1 18 (60%) 15 (50%) 0.642 0.667 0.61 95
PONV 2 9 (30%) 13 (43.3%)
PONV 3 3 (10%) 2 (6.6%)
At 6 post-operative hours PONV 1 30 (100%) 23 (76.6%) 0.020 0 - 95
PONV 2 0 (0%) 5 (16.6%)
PONV 3 0 (0%) 2 (6.6%)
PONV: Post-operative Nausea and Vomiting.
have led to a number of experiments further suggesting the
action of benzodiazepine and its agonists. Nishiyama reports
that midazolam, which is itself a water soluble
benzodiazepine derivative by virtue of being a
benzodiazepine-GABAA receptor complex agonist, exhibits
synergistic analgesia for thermally-induced acute nociception
as well as persistent inflammatory nociceptive activation both
with N-Methyl-DAspartica Acid (NMDA) and 2-amino-3-(5-
methyl-3-oxo-12-oxazol-4-yl) Propanoic Acid (AMPA)
receptor antagonists.18 Goodchild et al also reported that
intra-thecal midazolam caused spinally mediated anti-
nociception by a mechanism involving opioid receptor
activation, and Bahar et al showed its anaesthetic affects.19,20
Gibbons et al21 proposed using absorbable gelatin
sponge contoured to the laminotomy defect, soaked in
methylprednisolone acetate and preservative-free morphine,
and concluded that this method provides effective, safe and
extended analgesia after lumbar discectomy. We used the
same method to deliver midazolam to our patients. The mean
age of patients included in our study was 38 years which is
consistent with literature.1 Published literature does not
support any gender predisposition for intervertebral disc
herniation, but in our study we found an overwhelming male
predominance (68% male patients), consistent with other local
studies showing male predisposition in pathologies which
otherwise are not known to show gender predilection.22-24
Mean VAS at one hour post-surgery was more for patients in
group B (6.07) as compared to patients in group A (5.57),
possibly suggesting some degree of analgesia provided by the
epidural midazolam. The VAS thereafter showed gradual
decline at 6, 12, 24 and 48 hours and the difference between
groups becomes insignificant. On analysis of post-operative
ambulation, we found that patients who were administered
midazolam were able to initiate ambulation much earlier as
compared to the other group. This became a significant
difference (p = 0.005). By the sixth post-operative hour, 54 (90
%) of the patients were mobile without any support and the
difference became less significant (p = 0.335). 
Side effects of midazolam are unusual and mostly seen
with large intravenous or oral ingestion, and include sedation
and amnesia. Studies have ruled out any potential for
neurotoxicity if the dosage is kept within the safety
range.5,7,8,18-22 Nishiyama experimented with epidurally
administered midazolam in dogs and measured serial serum
and cerebrospinal fluid drug concentrations and concluded
that the cerebrospinal fluid concentrations are only 3% of
those in the systemic circulation.7 Other potential adverse
effects include changes in spinal somatosensory evoked
potentials, which have also been disregarded on the basis of
several well-conducted human and animal studies.5,8,27-29
Repeated motor and sensory examinations carried out in all
our patients also ensured no alterations in axonal transport.
Sedation was monitored using the Ramsay scale and only two
patients showed any degree of sedation, suggesting that
epidural midazolam had no effect on sedation. Blood pressure
monitoring was also carried out in all patients and no
significant alteration in haemodynamics was found. Post
operative nausea and vomiting was measured using the PONV
scoring system described by Wilson et al and later used by
Pandey et al.29 There are several studies which suggest that
midazolam, when used pre-operatively, significantly reduces
post-operative nausea and vomiting when administered either
per oral or as intravenous formulations.30,31 On comparing the
two groups, nine (30%) patients in group A and 13 (43.3 %) in
group B had mild nausea or single emetic episode (PONV
score 2) at the end of first post-operative hour. Apart from
these, three (10 %) patients in group A and 2 (6.6 %) in group
B also had one or two emetic episodes or moderate to severe
nausea requiring anti-emetic therapy (PONV score 3).
However, at the end of the sixth post-operative hour, no
patient in group A and five (16.6 %) in group B had PONV
score of 2 (p =0.020). These results suggest that midazolam
may have an affect on PONV at one and six hours (p =0.642
and 0.020 respectively). The only complication noticed in the
study was post-operative urinary retention. None of the
patients in our study showed any reduction in their hip joint
power or lower extremity temperature sensations at any point
in their post-operative course.
The investigator most noted for his work on midazolam
as an epidural analgesic is Nishiyama.6,7,18Most of his work is
done on patients undergoing abdominal surgery. He has
concluded that epidural midazolam increases the central
analgesic, sedative and amnesic effects of spinal analgesia and
is useful for managing post-operative pain. In all of these
studies epidural midazolam did not show any effect on patient's
haemodynamics just as was the case in our study. We used
much lower doses of midazolam as compared to Nishiyama et
al, as the post-operative analgesic requirements following
microdiscectomy are far lower than those following abdominal
surgery.6,7,18 In Nishiyama's studies, the investigators were able
to achieve better post-operative pain control as compared to
our study, though at the expense of more sedation.6,7,18 Such an
effect may be desirable after upper abdominal surgery, but after
microdiscectomy when early ambulation is the goal, pain relief
at the expense of sedation is not justified. We, however, found
that patients who received epidural midazolam were able to
initiate ambulation much earlier than the other group. This
finding has not been previously addressed and we reckon that
if a definite cause-effect relationship can be established, this
one possible advantage of epidural midazolam is significant
enough to recommend its routine use. 
Conclusion
Midazolam when administered through the epidural
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route in a small dose is safe. It does not have significant anti-
nociceptive effect, but it may improve post-operative nausea,
vomiting, and may lead to earlier ambulation without
affecting a patient's vitals, conscious status, lower extremity
power or sensations. A larger sample size is recommended to
further improve the significance of these findings.
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